Pharmasset Newswire (Page 3)

Pharmasset Newswire (Page 3)

Comprehensive Real-Time News Feed for Pharmasset. (Page 3)

Results 41 - 55 of 57 in Pharmasset

  1. Gilead: How Sweet It IsRead the original story w/Photo

    Jun 23, 2017 | Seeking Alpha

    ... 5:37 PM EDT) -- A Federal Circuit panel on Wednesday affirmed a Patent Trial and Appeal Board ruling that Gilead Pharmasset LLC invented a hepatitis C treatment before Idenix Pharmaceuticals LLC and will be granted a patent. The court evaluated ...


  2. 3 History-Making StocksRead the original story w/Photo

    Jun 3, 2017 | The Motley Fool

    ... news is that Gilead has a pretty good track record of making deals. In 2011, the biotech spent $11 billion to buy Pharmasset -- picking up a drug later to be called Sovaldi. Jordan Wathen has no position in any stocks mentioned. Keith Speights owns ...


  3. 3 Stocks That Generate Tons of CashRead the original story w/Photo

    May 9, 2017 | The Motley Fool

    ... infectious disease portfolio with inorganic growth. The last time Gilead made a large acquisition, it acquired Pharmasset for $11 billion in 2011 and set the foundation for its dominant HCV product portfolio. Not to mention, this cash flow is ...


  4. Cash is always king for the true survivors of global stock marketsRead the original story w/Photo

    May 7, 2017 |

    ... patients using Gilead's products provide an attractive recurring revenue stream. In 2012, Gilead acquired Pharmasset for $10.6bn (a 9.7bn). Pharmasset's main asset was a potential cure for Hepatitis C that had shown excellent clinical trial results. ...


  5. AAFP Joins Campaign to Push Against Rising Drug PricesRead the original story w/Photo

    Apr 7, 2017 | American Academy of Family Physicians

    ... prices and development costs, the campaign noted that the hepatitis C drug sofosbuvir (Sovaldi) was developed by Pharmasset, a small company whose primary funding came from the NIH. Yet despite taxpayers having largely footed the bill for developing ...


  6. Gilead Sciences: The Bull, the Bear and the Fence-SitterRead the original story w/Photo

    Apr 6, 2017 | The Motley Fool

    ... and this cash flow gives it the ability to do just that. Remember, the last major purchase Gilead made was Pharmasset, for $11 billion, and that only fueled its entire HCV product portfolio. With Gilead valued at just nine times forward earnings, ...


  7. Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just boughtRead the original story w/Photo

    Mar 16, 2017 | MarketWatch

    ... Marathon paused its launch , noting pushback from the DMD community. Sovaldi intensified upon the discovery that Pharmasset Inc., which developed the drug, projected it would cost about $36,000 per course of treatment. Emflaza in particular garnered ...


  8. Gilead: Is Management The Issue?Read the original story w/Photo

    Feb 22, 2017 | Seeking Alpha

    ... stock's ~24-month slide mounts. Once lauded as "geniuses" for acquiring it hepatitis C franchise by purchasing Pharmasset for a "mere" $11 billion in 2011, management is increasingly referred to as overpaid incompetents. The criticism generally ...


  9. Why Gilead Sciences Is a BuyRead the original story w/Photo

    Feb 19, 2017 | The Motley Fool

    ... acquisitions, and I'll talk briefly about a couple of them. When they bought Triangle Pharmaceuticals in 2003 and Pharmasset in 2012, in both cases, there was a lot of speculation by analysts that they overpaid. Triangle provided an HIV drug called ...


  10. Gilead's HCV Guidance Wasn't SandbaggedRead the original story w/Photo

    Feb 17, 2017 | Seeking Alpha

    ... model investors love and why. All the talk surrounding Gilead (NASDAQ: GILD ) for the last few years since the Pharmasset acquisition has been centered around the HCV revenue stream from sofosbuvir-based products. Recently, Gilead guided HCV revenue ...


  11. Pharma M&A In 2017: The Most Likely Deal HuntersRead the original story w/Photo

    Feb 12, 2017 | Seeking Alpha

    ... to re-discover the magic elixir of growth through another transformative deal like it did with Triangle and Pharmasset (that yielded Sovaldi). With a cash pile of USD 32bn and low leverage (Expected 2017 Debt / Ebitda is expected to be less than 2) ...


  12. Cramer: Here's the Reason for Allergan's Remarkable RunRead the original story w/Photo

    Feb 9, 2017 |

    ... what did Gilead ( GILD ) do to get into the Hepatitis C segment? It spent $11 billion, an 89% premium, to acquire Pharmasset, which had a promising potential cure for the often fatal disease. It's more important now than ever to return to the old ...


  13. 'Want to know why Allergan was up so much? Look at why Gilead was down.'Read the original story w/Photo

    Feb 9, 2017 |

    ... what did Gilead (GILD) do to get into the Hepatitis C segment? It spent $11 billion, an 89% premium, to acquire Pharmasset, which had a promising potential cure for the often fatal disease....349 more words left in this article. To read them, just ...


  14. 3 attractive income stocks whose dividends could doubleRead the original story w/Photo

    Feb 8, 2017 | USA Today

    ... acquisitions and boost its shareholder yield. Remember, the last time Gilead made a big acquisition it acquired Pharmasset's leading asset, which spawned its HCV line of drugs. Currently paying out $1.88 annually (a 2.6% dividend yield), but slated ...


  15. The Single Most Important Number for Gilead SciencesRead the original story w/Photo

    Jan 29, 2017 | The Motley Fool

    ... equivalent of a wise dairy farmer? I think so. In November 2011, Gilead Sciences announced that it was acquiring Pharmasset for $11.2 billion. Gilead had free cash flow of roughly $3.5 billion in 2011. That acquisition led to Sovaldi, which led to ...